In this special edition of PharmaVentures Insights, Dr Fintan Walton, CEO & Founder of PharmaVentures, leads a panel discussion to address whether a dual fundraising and partnering strategy is the best way forward for an emerging biotech.
Panelists include Tomas Landh, Innovation Sourcing VP, Senior Principal Scientist Search and Evaluation at Novo Nordisk, Jeanne Bolger, Vice President, Venture Investments at Johnson & Johnson Innovation, Bart Dzikowski, Managing Director, Head of Transactions & Legal at Novartis Venture Fund, Tim Luker, Senior Director, External Innovation, Global External R&D at Eli Lilly and Company, and Kevin Johnson, Co-Founder at Medicxi.
Panel recording is available via this link: https://www.pharmaventures.com/special-edition-a-combined-fundraising-pa...
Fintan Walton, CEO & Founder, PharmaVentures